Novel approach to determine ghrelin analogs by liquid chromatography with mass spectrometry using a monolithic column
Jazyk angličtina Země Německo Médium print-electronic
Typ dokumentu časopisecké články
PubMed
27995738
DOI
10.1002/jssc.201601141
Knihovny.cz E-zdroje
- Klíčová slova
- enzyme-linked immunosorbent assay, ghrelin, lipopeptides, liquid chromatography mass spectrometry, monolithic columns,
- MeSH
- chromatografie kapalinová * MeSH
- ghrelin analogy a deriváty MeSH
- kalibrace MeSH
- lipopeptidy krev MeSH
- reprodukovatelnost výsledků MeSH
- tandemová hmotnostní spektrometrie * MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- ghrelin MeSH
- lipopeptidy MeSH
In our project, ghrelin analogs possessing enhanced stability and potential to significantly increase food intake were used. Three newly synthesized ghrelin analogs with fatty acid residues consisting of 8, 10, and 14 carbon atoms were studied. The main goal of this work was to develop a suitable analytical method for the determination of the stability of the novel ghrelin analogs in plasma. An appropriate liquid chromatography-mass spectrometry method was developed and optimized. The results obtained were compared with the data measured by using a commercial enzyme-linked immunosorbent assay kit, and a good correlation was found. A preparation strategy for plasma samples was optimized and consisted of simple dilution of the plasma samples followed by direct injection onto a very short monolithic column in combination with mass spectrometric detection. The developed analytical method was utilized for the determination of the stability of the prepared lipopeptides in plasma and for the quantification of the lipopeptides in a preliminary pharmacokinetic study. The feasibility of the developed separation method was clearly demonstrated. Accuracy and precision were within 80-120% and ±20% limits, respectively. Calibration curves were constructed in the range of 1-250 μg/mL.
Citace poskytuje Crossref.org
Lipidization as a tool toward peptide therapeutics